From individual practitioners to sovereign mandates, every tier runs adversarial audits against your briefs and returns a source-traced verdict: PROCEED, DELAY, or KILL. Healthcare intelligence needs a verification layer. Be the team that built it first.
Walk the Member, Signal, Shield, and Command desks with sample data.
Four entry points. Pick the one that matches who you are. You can always switch paths later.
Physicians, researchers, clinicians, regulatory consultants, independent experts. Personal access. Adversarial validation on the briefs you actually use.
Biopharma teams, health systems, compliance groups, enterprise buyers. Multi-user workflows. Governance, monitoring, board-ready verdicts.
Verified experts contributing review, perspective, and professional signal interpretation. Network participation, not a subscription.
Quick intake call. Three questions, one recommendation. No commitment, no sales pressure. The fastest way to land in the right room.
Every practitioner using general-purpose AI for clinical or regulatory decisions is inheriting hallucination risk they cannot see. These tiers are designed to reduce that exposure with containment architecture and source-traced verification on every output.
Most individual professionals start with Member at $199/month. Users who need category monitoring start with Signal at $279/month.
Pick the one that matches how you decide.
“I need an ongoing intelligence workspace.”
Signal, Shield, Command (below). A regularly refreshed signal workspace across your therapeutic areas. Watchlist setup available during onboarding. Monthly subscription.
From $279 / month.
“I need evidence on a specific entity, on demand.”
AIMN:VERDICT. Click any of thousands of company and entity references across the raw indexed corpus, get a cited 2 to 3 page verdict in 90 seconds. Pay for verdicts, not monitoring.
See VERDICT → · From $199 / month.
Many institutional members run both. VERDICT for the deep dive. A Signal tier so nothing moves while they are not looking.
A monitored portfolio across 9 therapeutic areas. For less than one retainer day.
"I can monitor." Signal watches your whole category so one missed FDA guidance change never reaches a decision. The monitoring climb above Member.
Watchlists, an expanded feed, digests, alerts, and the signal archive. Your first layer of verified clinical and regulatory signal protection. Without Signal, you are approving or rejecting intelligence without a monitoring layer.
“How comfortable are you with the AI summaries currently entering your patient charts?”
"I can protect decisions." If a competitor readout or a label-narrowing signal surprises you in a board memo, the cost is measured in credibility, not dollars. Shield is designed to make that kind of surprise harder to miss.
Risk flags, dossiers, regulatory movement, confidence history, and advanced exports. The dossier layer is in activation, configured during onboarding. Daily intelligence protection for professionals who cannot afford to be surprised. Without Shield, you have verdicts and signals but no risk-flag layer for decisions. Shield is currently available by request while dossier and risk-room workflows are being activated. The $449/mo price stands, access is granted by request rather than instant checkout.
“What would change in your next board memo if every signal in it came with a defensible verdict?”
"I can run intelligence workflows." Your team operating on the same intelligence grade as the institutions you compete with. The asymmetry, removed.
Decision rooms, briefing exports, team workflow, and the Command dashboard. A private intelligence command layer for teams making high-consequence decisions.
Command turns signals, verdicts, and dossiers into team decision rooms. Designed for the decision room itself, the briefing export, the saved signal set, the team review queue, the evidence trail, and the stakeholder-ready briefing. Scoped through review, request-based rather than instant checkout.
“What changes when your practice is operating on the same intelligence as the institutions you compete with?”
Command deployments are configured with Aimwell review before activation. Your verdict history, your decision trail, your blind-spot map. Every month it deepens. It is the one intelligence asset that is yours, and the one thing you cannot rebuild if you leave.
Request Command / EnterpriseDossiers unlock with Shield. Track risk patterns, regulatory movement, and company/category intelligence in one place. Most teams start on Signal and move to Shield once a second indication or a board memo enters the picture. You can change tier at any billing cycle, your vault and verdict history move with you.
Compare Signal vs. Shield →No screenshots of features that do not exist yet. Three columns: what is delivered and active on day one, what is configured during your onboarding, and what happens the moment your subscription starts.
Want to see the actual tier dashboards before you decide? Preview every tier dashboard → · Sample data in previews is labeled Sample; live data connects in your environment after onboarding.
Citation-eligible SVG credential. LinkedIn-embeddable. Yours, not ours, portable even if you leave.
See all tier badges →The methodology reference. Full 60-page edition + acknowledgments-page citation. Released Sept 2026.
See the Standard →Applies to Signal, Shield, and Command. Within the first 30 days, if you can name a regulatory or competitive signal in your indication that AimwellBio should have surfaced and didn’t, we refund the month and you keep the data you generated. We make this promise because we have to keep it. Decision integrity is the product. If it fails, so do we.
This is also why members stay. If it ever stops earning its place, you would already know, because we would have refunded the month it did.
The organizations deploying Cortex now are building institutional intelligence assets that grow stronger every week. The longer you wait, the wider the gap becomes between what they know and what you're guessing at.
$80,000 to $250,000 per seat per year for a fragmented stack that delivers neutral compilations, not verdicts.
Five logins. Five invoices. The analyst still assembles the verdict by hand. AimwellBio Enterprise starts at $120,000 / year with verdict integrity included.
Cheaper than one mid-level analyst, and it does not leave with 14 months of context in its head.
For biotech and pharma teams scaling from ad-hoc intelligence to structured decision support.
Growth-stage companies · 50 to 500 employees
The institutional memory layer is yours. Every verdict, every decision, every blind spot mapped by your team accumulates inside your deployment. It is the one intelligence asset that compounds while you sleep, and the one thing you cannot rebuild if you cancel.
See the network →"My team can deploy this." Less than the fully loaded cost of a single regulatory consultant engagement, delivering on an ongoing cadence instead of once.
A private workspace, team seats, custom monitoring, and department dashboards. Need this for a team, department, or portfolio? Enterprise unlocks private workspaces, team seats, and custom monitoring. For organizations that require adversarial validation runs at scale, with full audit trails and board-level verdict packages.
Enterprise deploys the intelligence workflow across a team, institution, or portfolio. Designed for team seats, governance, reporting, source requirements, pilot design, integration review, and renewal metrics. Scoped through review, available by enterprise conversation rather than instant checkout.
Request Enterprise Conversation →Enterprise & institutional · 500+ employees
Your audit trail, your asset. Every PROCEED, DELAY, and KILL verdict your organization runs accrues to a private institutional memory only your team can query. It survives turnover, board changes, and reorgs. It does not transfer if you leave.
See the network →All enterprise packages include a guided intelligence assessment, white-glove onboarding, and full Decision Integrity Engine deployment. Professional plans start immediately with self-serve onboarding.
See what every tier looks like before you commit.
Open the tier preview gallery →From a solo practitioner subscribing to five different services that contradict each other, to a national health system spending hundreds of millions on consultants who deliver PowerPoints six months late. The same structural failure repeats at every scale.
Individual practitioners today piece together intelligence from general-purpose AI tools, generic databases, paid newsletters, and conference hearsay. None of it is verified. None of it is cross-referenced. Every decision carries hidden hallucination risk that one person cannot detect alone.
Growth-stage biotech companies spend millions on competitive intelligence teams, regulatory consultants, and market research firms. When an analyst leaves, their knowledge walks out the door. There is no compounding. No structured memory. Every new hire starts from zero.
Enterprise pharma organizations pay the largest consulting firms in the world for intelligence that arrives as static PDF decks, months after the signals were relevant. The reports cannot update themselves. They do not learn. And the next engagement starts fresh, as if the last one never happened.
National health systems and sovereign wealth funds have spent billions building intelligence infrastructure that failed catastrophically when it was needed most. Fragmented data systems, conflicting regulatory signals across jurisdictions, and zero verified cross-border intelligence coordination. The cost of that failure was measured in trillions of dollars and millions of lives.
The legacy model charges more at every level of scale and delivers less at every level of speed. Cortex inverts that equation: verified intelligence that gets stronger the more you use it, at a fraction of what you are paying today to guess.
Signal works well for startups and early-stage teams building initial intelligence capabilities. Shield is designed for growth-stage organizations with dedicated teams and higher operational complexity. Command is built for enterprise settings, board-level decision-making, and environments requiring maximum control and customization. We recommend scheduling an intelligence assessment, our team will help you determine the best fit.
Yes. We design packages to grow with your organization. Most customers start at one tier and evolve as their needs change. Upgrades take effect immediately. Downgrades are processed at the end of your current billing period. Our team manages all transitions to ensure continuity.
Every package includes a 30-60 day onboarding period. We begin with a guided intelligence assessment to map your competitive landscape, regulatory environment, and key decision-makers. We then configure the platform, populate your initial institutional memory, and train your team on workflows that match your business processes. Dedicated onboarding (Shield and Command) includes a dedicated analyst to ensure smooth adoption.
Most customers commit to 12 months to allow time for proper implementation and value realization. For larger deployments or custom integrations, we can discuss longer terms. All contracts include clear success metrics and SLA commitments with defined credits through our SLA commitments.
Your institutional memory and all intelligence outputs remain yours. We provide data export in standard formats (JSON, CSV, PDF) is in activation, so you maintain control of everything your organization creates. We can facilitate handoff to your own systems or provide guidance on next steps. Data retention is governed by your contract and our privacy policy.
That is a fair question to sit with. The honest framing: one missed FDA guidance change or an unsupported claim that reaches a board memo costs more than a year of any tier here. You also do not have to take that on faith. Every paid tier carries the 30-day Verdict Refund Pledge, if a signal that mattered in your indication was not surfaced, we refund the month and you keep the data you generated. The intelligence is meant to prove itself before you are locked into anything.
For Signal, Shield, and Command, you can change tier at any billing cycle and your verdict history and Member Badge move with you, they are yours, not ours, and exportable even if you leave. Larger Institutional and Sovereign deployments do involve a longer term, because implementation and data residency take time to do properly; those terms are spelled out in the contract before you sign, never assumed. Nothing self-serve commits you beyond the month you are in.
It is a real product, and we are deliberate about which parts are active today versus in activation. Active on day one: AIMN:VERDICT verdict generation, private vault read and write, and AIMN:ATLAS access. In activation during onboarding: the signal feed, alerts, watchlist, dossier, competitor monitoring, these are configured for your indications rather than switched on blindly, and simulation tooling is planned on the roadmap. You can preview every tier dashboard before deciding; sample data in those previews is labeled Sample.
Straight answer: AIMN:VERDICT resolves citations against upstream sources, PubMed, ClinicalTrials.gov, SEC EDGAR, OpenFDA, and bioRxiv, at the time a verdict is generated, and each source is only as current as its upstream database. We do not claim a feed that never sleeps. The signal feed and monitoring layers are in activation and are configured during onboarding to refresh on a defined cadence for your indications, not on an unbounded promise. Every output is source-traced so you can see exactly where each claim came from.
Not ready to start? The Observer tier is free for credentialed professionals, no card, no commitment. Create a free Observer account →
Which path on this page matches the decision you would lose sleep over getting wrong?
Plus: every paid tier includes the Member Badge (citation-eligible, portable) + 30-day Verdict Refund Pledge + access to The Adversarial Validation Standard on release.
Hand us anything your team is about to use. We return a source-risk review with every citation traced. No sales call. No follow-up sequence. The review itself is the conversation.
Teams searched documents, reviewed guidance updates, followed trial movement, tracked competitors, and built internal briefs by hand. Slow but auditable. Every claim had a paper trail.
Speed. The same brief that took a week now takes minutes. The trade-off: unsupported claims, stale guidance, missing context, and incomplete summaries can now move into serious decisions before anyone challenges them.
AimwellBio is the verification layer that sits between AI-generated intelligence and the decision someone signs their name to. Source-trace, adversarial review, confidence labels, institutional memory.
Seven ways unsupported scientific intelligence can enter regulatory, clinical, board, and investor workflows. Open to credentialed professionals. No sales sequence, no list-trading.